XAV939 is a small molecule inhibitor that targets the Wnt/beta-catenin signaling pathway. This pathway plays an essential role in regulating cell growth and differentiation, making it a potential therapeutic target for cancer treatment.
Chemical name: Ethyl 3-(pyridin-4-yl)-N-(4-(aminosulfonyl)phenyl)propanamide
Molecular formula: C16H18N4O3S
Formula weight: 346.41 g/mol
CAS No: 284028-89-3
Top ten keywords from Google and Synonyms:
Health benefits of this product: Studies have shown that XAV939 has potent anti-tumor effects in a variety of cancers, including colon, lung, liver, breast, and pancreatic cancer. It works by inhibiting the Wnt/beta-catenin signaling pathway, which is important in tumor growth and progression. Additionally, XAV939 may also have neuroprotective effects and could potentially be used to treat neurological disorders such as Alzheimer's disease.
Potential effects: As a Wnt/beta-catenin inhibitor, XAV939 has the potential to slow or stop tumor growth in a variety of cancers. It may also have neuroprotective effects that could be useful in treating neurological disorders. However, more research is needed to fully understand the potential effects of XAV939.
Product mechanism: XAV939 works by inhibiting the Wnt/beta-catenin signaling pathway. This pathway plays an essential role in regulating cell growth and differentiation. In cancer cells, this pathway is often overactive, leading to uncontrolled cell growth and tumor formation. XAV939 binds to a protein called tankyrase, which is involved in regulating the Wnt/beta-catenin pathway, and prevents its activity. This leads to a reduction in the activity of the pathway and subsequently slows or stops tumor growth.
Safety: XAV939 has been shown to be generally safe in preclinical studies, but more research is needed to fully understand its safety profile in humans. As with any drug, there is a risk of adverse effects, especially when used at high doses or for prolonged periods. Patients should consult their healthcare provider before beginning treatment with XAV939.
Side effects: The most common side effect of XAV939 in preclinical studies was mild gastrointestinal upset, including nausea and diarrhea. Other potential side effects may include liver toxicity, skin rash, and bone marrow suppression. Patients should report any severe or persistent side effects to their healthcare provider.
Dosing information: XAV939 dosing varies depending on the indication and patient factors such as age, weight, and overall health. It is typically administered orally, either alone or in combination with other cancer drugs. Patients should follow their healthcare provider's dosing instructions carefully and report any missed doses or changes in symptoms.
Conclusion: XAV939 is a promising drug candidate for the treatment of cancer and neurological disorders. Its ability to inhibit the Wnt/beta-catenin signaling pathway makes it a potentially valuable tool in slowing or stopping tumor growth. However, more research is needed to fully understand its potential effects and safety profile in humans. Patients should consult their healthcare provider before beginning treatment with XAV939 and report any severe or persistent side effects